Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...

Fintel reports that on July 18, 2025, Jefferies upgraded their outlook for Abbott Laboratories (NYSE:ABT) from Hold to Buy.

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories (NYSE:ABT) now projects organic sales growth, excluding COVID-19 testing-related sales, to grow between 7 ...

Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still ...

Abbott Laboratories ABT is preparing to release its quarterly earnings on Thursday, 2025-07-17. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Abbott Laboratories closed 14.67% below its 52-week high of $141.23, which the company achieved on March 4th.

The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.